Patent EP0138667B1 successfully refreshed from Google Patents.
← Back to Patent Explorer
EP0138667B1 Expired / Lapsed EP ⏱️ 0.0 years remaining

Method for the diagnosis of lymphadenopathy and acquired immune depression syndrome

Assignee: Institut Pasteur
•
Filing: 1984-09-14
•
Granted: 1991-11-21
•
Expires: 2004-09-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

No abstract record available.

Inventors

  • 👤 Luc Montagnier
  • 👤 Jean-Claude Cherman
  • 👤 Françoise Barre-Sinoussi
  • 👤 Françoise Vizinet-Brun
  • 👤 Christine Rouzioux
  • 👤 Willy Rosenbaum
  • 👤 Charles Dauguet
  • 👤 Jacqueline Gruest
  • 👤 Marie-Thérèse Nugeyre
  • 👤 Françoise Ray
  • 👤 Claudine Axler-Blin
  • 👤 Solange Chamaret

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-03 09:43
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C12; C12Q; C12Q1/00; A; A61; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; C12N; C12N7/00; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; G01N33/56988; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16021; C12N2740/16051; C12N2740/16211; C12N2740/16222; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/8215; Y10S435/948; Y10S435/974; Y10S436/00; Y10S436/804; Y10S436/807; Y10S436/808; Y10S436/811

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 133 words
A method for the in vitro diagnosis of a LAS or of AIDS, characterized, - in that one brings into contact a serum or another biological medium obtained from a patient who is subject to said diagnosis, with a purified p25 protein, which exhibits a molecular weight of about 25,000, immunologically distinct from the p19 and p24 proteins of HTLV1, obtained from an extract of one of the retroviruses deposited at the C.N.C.M. under numbers I-232, I-240 or I-241 or of one of their mutants or variants, or with a proteic fraction of said purified p25 protein and which is liable of providing an immunological reaction with antibodies directed against the purified p25 protein - in that one detects the possible immunological reaction between said protein and said serum or other biological medium.
Claim 2
Dependent Claim 151 words
A kit for the in vitro detection of a LAS or of AIDS in serums originating from patients, characterized in that it comprises: - a purified p25 protein exhibiting a molecular weight of about 25,000, immunologically distinct from the p19 and p24 proteins of HTLV1, obtained from the extract of one of the retroviruses deposited at the C.N.C.M. under numbers I-232, I-240 and I-241 or of one of their mutants or variants, or a proteic fraction of said purified p25 protein and capable of giving rise to an immunological reaction with antibodies directed against said purified p25 protein, said protein or proteic fraction being labelled, - human anti-immunoglobulins, - an extract of lymphocytes obtained from a healthy person, - buffers and, possibly, substrates for the visualization of the labelling, - means for detecting the labelled conjugate resulting from the immunological reaction between the labelled protein or proteic fraction and the serums.
Claim 3
Dependent Claim 149 words
A kit for the dosage of AIDS or of a LAS, characterized in that it comprises: - a purified p25 protein exhibiting a molecular weight of about 25,000, immunologically distinct from the p19 and p24 proteins of HTLV1, obtained from an extract of one of the retroviruses deposited at the C.N.C.M. under numbers I-232, I-240 and I-241 or from one of their mutants or variants, or with a proteic fraction of said purified p25 protein and liable of giving rise to an immunological reaction with antibodies directed against said purified p25 protein, said protein or proteic fraction being labelled, - human anti-immunoglobulins, - a lymphocytes extract obtained from said healthy person, - buffers and, possibly, substrates for the visualization of the labelling - means for dosing the labelled conjugate resulting from the immunological reaction between the labelled protein or proteic fraction and the biological medium subjected to the dosage.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag